Biopharma companies are showing signs of recovery as they work through another quarter of deal and funding challenges. On the medtech front, activity remains muted—but there are pockets of positive data.
Biopharma venture activity increased in the second quarter of 2023, even as R&D partnerships declined to their lowest quarterly volume in more than five years.
J.P. Morgan’s biopharma therapeutics and medtech licensing reports explore the movement in each sector, offering insight on industry trends that will shape the back half of 2023. The reports, powered by DealForma, highlight:
- Deal values in biopharma licensing partnerships
- Trends in deal values for medical devices, diagnostics, digital health therapies and research tools
- Venture investment amounts in therapeutic and platform companies
- The advanced therapies that are seeing healthy investment and dealmaking
- IPO and M&A activity in each sector
Download the full reports to better understand these dealmaking trends.
